Millennium Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $37.1M | Buy |
1,772,184
+891,540
| +101% | +$20.1M | 0.02% | 1060 |
|
|
2025
Q4 | $20.3M | Buy |
880,644
+781,431
| +788% | +$25.7M | 0.01% | 1564 |
|
|
2025
Q3 | $2.98M | Sell |
99,213
-387,128
| -80% | -$11.6M | ﹤0.01% | 3669 |
|
|
2025
Q2 | $17.7M | Sell |
486,341
-226,052
| -32% | -$8.15M | 0.01% | 1704 |
|
|
2025
Q1 | $25.8M | Buy |
712,393
+15,157
| +2% | +$631K | 0.01% | 1276 |
|
|
2024
Q4 | $29.3M | Sell |
697,236
-13,453
| -2% | -$667K | 0.01% | 1202 |
|
|
2024
Q3 | $39.5M | Sell |
710,689
-1,140,045
| -62% | -$58.1M | 0.02% | 988 |
|
|
2024
Q2 | $76.1M | Buy |
1,850,734
+1,142,829
| +161% | +$48.8M | 0.04% | 554 |
|
|
2024
Q1 | $33.1M | Buy |
707,905
+679,353
| +2,379% | +$32M | 0.01% | 1123 |
|
|
2023
Q4 | $1.37M | Sell |
28,552
-80,396
| -74% | -$3.12M | ﹤0.01% | 3915 |
|
|
2023
Q3 | $3.88M | Buy |
108,948
+53,503
| +96% | +$2.12M | ﹤0.01% | 2950 |
|
|
2023
Q2 | $2.56M | Sell |
55,445
-706,402
| -93% | -$32.8M | ﹤0.01% | 3261 |
|
|
2023
Q1 | $30.6M | Sell |
761,847
-10,880
| -1% | -$467K | 0.02% | 1009 |
|
|
2022
Q4 | $35.8M | Buy |
772,727
+477,325
| +162% | +$18.8M | 0.02% | 987 |
|
|
2022
Q3 | $12.2M | Buy |
295,402
+171,571
| +139% | +$8.82M | 0.01% | 1893 |
|
|
2022
Q2 | $7.39M | Buy |
123,831
+116,413
| +1,569% | +$7.16M | ﹤0.01% | 2379 |
|
|
2022
Q1 | $539K | Sell |
7,418
-55,822
| -88% | -$3.88M | ﹤0.01% | 5062 |
|
|
2021
Q4 | $5.32M | Sell |
63,240
-44,524
| -41% | -$3.62M | ﹤0.01% | 2842 |
|
|
2021
Q3 | $9.72M | Sell |
107,764
-455,623
| -81% | -$41.2M | 0.01% | 2091 |
|
|
2021
Q2 | $53.7M | Buy |
+563,387
| New | +$58.7M | 0.03% | 569 |
|
|
2021
Q1 | – | Sell |
-2,095
| Closed | -$285K | – | 6416 |
|
|
2020
Q4 | $290K | Sell |
2,095
-3,858
| -65% | -$458K | ﹤0.01% | 4570 |
|
|
2020
Q3 | $489 | Sell |
5,953
-49,570
| -89% | -$4.11M | ﹤0.01% | 3591 |
|
|
2020
Q2 | $4.34M | Buy |
55,523
+42,129
| +315% | +$2.79M | 0.01% | 1913 |
|
|
2020
Q1 | $595K | Buy |
+13,394
| New | +$695K | ﹤0.01% | 2781 |
|
|
2019
Q4 | – | Sell |
-5,813
| Closed | -$248K | – | 4560 |
|
|
2019
Q3 | $248K | Buy |
+5,813
| New | +$316K | ﹤0.01% | 3667 |
|
|
2018
Q4 | – | Sell |
-17,362
| Closed | -$1.32M | – | 4096 |
|
|
2018
Q3 | $1.32M | Buy |
+17,362
| New | +$1.41M | ﹤0.01% | 2709 |
|
|
2018
Q2 | – | Sell |
-300,260
| Closed | -$15.3M | – | 4109 |
|
|
2018
Q1 | $15.3M | Buy |
300,260
+176,425
| +142% | +$8.88M | 0.02% | 1047 |
|
|
2017
Q4 | $5.74M | Buy |
123,835
+37,315
| +43% | +$1.83M | 0.01% | 1673 |
|
|
2017
Q3 | $4.61M | Buy |
+86,520
| New | +$5.13M | 0.01% | 1721 |
|
|
2017
Q2 | – | Sell |
-3,920
| Closed | -$266K | – | 3790 |
|
|
2017
Q1 | $266K | Buy |
+3,920
| New | +$299K | ﹤0.01% | 3095 |
|
|
2016
Q4 | – | Sell |
-10,000
| Closed | -$709K | – | 3650 |
|
|
2016
Q3 | $709K | Sell |
10,000
-451,245
| -98% | -$28.8M | ﹤0.01% | 2445 |
|
|
2016
Q2 | $22.6M | Buy |
461,245
+175,350
| +61% | +$11.3M | 0.05% | 471 |
|
|
2016
Q1 | $18.1M | Buy |
285,895
+91,705
| +47% | +$6M | 0.05% | 530 |
|
|
2015
Q4 | $21.8M | Sell |
194,190
-347,499
| -64% | -$34.7M | 0.05% | 544 |
|
|
2015
Q3 | $52.2M | Buy |
541,689
+57,509
| +12% | +$6.58M | 0.1% | 231 |
|
|
2015
Q2 | $49.6M | Sell |
484,180
-497,666
| -51% | -$38.6M | 0.09% | 261 |
|
|
2015
Q1 | $61M | Buy |
981,846
+674,563
| +220% | +$37.5M | 0.11% | 200 |
|
|
2014
Q4 | $13.5M | Buy |
307,283
+303,283
| +7,582% | +$13.9M | 0.03% | 811 |
|
|
2014
Q3 | $226K | Sell |
4,000
-10,350
| -72% | -$521K | ﹤0.01% | 3326 |
|
|
2014
Q2 | $644K | Sell |
14,350
-63,781
| -82% | -$2.63M | ﹤0.01% | 2446 |
|
|
2014
Q1 | $3.82M | Buy |
+78,131
| New | +$4.02M | 0.01% | 1359 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Millennium Management's RARE Position: Q1 2026 in Review
Millennium Management increased its Ultragenyx Pharmaceutical (RARE) stake by 101% in Q1 2026, buying an estimated $20.1M and bringing the position to 1,772,184 shares worth $37.1M. The position accounts for 0.02% of the portfolio, ranked #1060.
Millennium Management first reported a position in RARE in Q1 2014 and has held it in 41 quarters since. The position peaked at $76.1M in Q2 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Millennium Management held 1,772,184 shares of Ultragenyx Pharmaceutical worth $37.1M as of Q1 2026.
- Millennium Management bought 891,540 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $20.1M.
- Ultragenyx Pharmaceutical made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1060 holding.
- Millennium Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 41 quarters since.
- Millennium Management's Ultragenyx Pharmaceutical position peaked at $76.1M in Q2 2024.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.